Clinical Trial Update: Metabolic Syndrome Risk Factor in IGT: STOP-NIDDM Trial [Phase 3]

View source ↗

Summary

Phase 3 STOP-NIDDM trial update examining metabolic syndrome risk factors in individuals with impaired glucose tolerance.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Impaired Glucose Tolerance
• Metabolic Syndrome

Drugs mentioned

• acarbose (Precose) (acarbose)

Snippet

Sponsor: GWT-TUD GmbH | Conditions: Metabolic Syndrome | Phase 3 | Status: COMPLETED